Pharma Equity Group A/S Class A PEG
OMXCOP · Denmark · Health Technology
DKK 0.0778+0.00 (+2.10%)
Market open· · DKK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · DKK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
07 September 2026 Announcement no. 11 Pharma Equity Group A/S – Challenge to Arbitral Award Pharma Equity Group A/S (“PEG”) has been notified that Interpatium – Promoção Imobiliária LDA has commenced proceedings before the District Court of Helsingør seeking to have the arbitral award dated 12 June 2026 set aside. PEG disputes the grounds for the proceedings and will protect the Company’s interests throughout the legal process. The commencement of the proceedings does not in itself suspend the e
Correction to Consolidated Interim Report 1 January – 30 June 202614 August 2026Announcement no. 10 The previous announcement with the half year report was missing the report. The announcement is re-published, including the report. On 14 August 2026, the Board of Directors and the Executive Board of Pharma Equity Group A/S ("PEG", "The Company" or the "Group") considered and approved the interim report for the Group for the period 1 January – 30 June 2026 ("H1 2026 report"), which can be summari
12 June 2026 Announcement no. 8 Pharma Equity Group prevails in international arbitration proceedings and is awarded EUR 10.5 million excluding interest and costs Pharma Equity Group A/S ("PEG" or the "Company") today announces that it has received a final and binding international arbitral award rendered by the Danish Institute of Arbitration in the proceedings against Interpatium – Promoção Imobiliária LDA, Madeira, Portugal. The Arbitral Tribunal has ruled entirely in favour of PEG and awarde
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.